Biomea Fusion Inc. shares advanced 5.8% in pre-market trading on Wednesday, lifting the stock to $1.45, as investors positioned for near-term clinical catalysts tied to the company’s oral GLP-1 program.
The move comes amid growing expectations for initial 28-day weight-reduction data from the Phase I GLP-131 clinical trial of BMF-650, an investigational oral GLP-1 receptor agonist. Biomea has guided that the data will be released in the third quarter of 2026, with the window described as entering its final weeks. The company’s guidance has drawn increased attention from analysts, including Citi, which placed an “upside 90-day catalyst watch” on the stock.
Biomea also highlighted progress in its obesity-focused OPAL study, noting on August 13 that the first patient had been dosed in the trial evaluating icovamenib in combination with semaglutide. Piper Sandler reiterated a Buy rating on August 14, adding to the upbeat sentiment.
The company’s second-quarter 2026 financial results, released earlier this month, showed a net loss per share of $0.12, beating the consensus estimate of $0.23. Despite the positive momentum, Biomea’s shares remain 51% below the 52-week high of $2.99, set in late 2024. The broader market presented a mild headwind, with the NASDAQ down roughly 0.7% and the S&P 500 off about 0.3%.
